Results 211 to 220 of about 61,821 (357)

Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

, 2023
Paul Haluska, Michael E. Menefee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald W. Northfelt, Theresa LaVallee, Shi Li, Xiang‐Qing Yu, Patricia Burke, Jaiqi Huang, Jaye L. Viner, Jennifer McDevitt, Patricia LoRusso   +12 more
openalex   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections. [PDF]

PLoS Pathog
Bu F, Ye G, Morsheimer K, Turner-Hubbard H, Eaton B, Anantpadma M, Bheemanapally K, Tan C, Davey R, Li F.   +9 more
europepmc   +1 more source

Supplementary Data from Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

, 2023
Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil Steven, T.R. Jeffry Evans, Alan Anthoney, Alexander N. Shoushtari, Omid Hamid, Avinash Gupta, Antonella Vardeu, Emma Leach, Revashnee Naidoo, Sarah Stanhope, Sion Lewis, Jacob Hurst, Anne M. Kelly, Mario Sznol   +18 more
openalex   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, EarlyView.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source

Advancing immunotherapy via multiple immune cells co-engagement. [PDF]

Front Immunol
Li H, Zhang Y, Wei Q, Sun Q, Lin F, Chen PR.   +5 more
europepmc   +1 more source

Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1

Gaurav Bajaj, Alexandra Diakonova, Sergey Smirnov, Anna Roskoshnaia, I Borisov, Patricia Garrido Castro, Nora Pencheva, Maria Jure‐Kunkel, Beesan Tan, Tim Maiwald, Manish Gupta, Oleg Demin, Craig J. Thalhauser   +12 more
openalex   +1 more source

1323 A novel bispecific antibody targeting CD137 and CLDN4 for treating patients with solid tumors [PDF]

Masahito Sato, Aya Kikuchi, Keita Nagaoka, Sumito Yoshida, Nicholas Souders, Masayasu Yoshino, Masayo Oishi, Hiroyuki Sayama, Takeshi Saito, Masashi Shimazaki, Kenna Shirasuna   +10 more
openalex   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source